Drug
HT 6184
HT 6184: highest development phase Phase 2, developed by Halia Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Halia Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| HT-6184 NCT07052006 | Phase 2 | Myelodysplastic Syndrome |
Latest
No recent events.
Follow HT 6184 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.